St. Joseph's Hospital and InNexus Biotechnology Ink Pact

Oct 03, 2008 (M2 PRESSWIRE via COMTEX) -- IXSBE | Quote | Chart | News | PowerRating -- St. Joseph's Hospital and Medical Center, part of Catholic Healthcare West, a healthcare system in the West with 42 hospitals in Arizona, California and Nevada, and InNexus Biotechnology, a drug development company commercializing monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, have announced a collaborative partnership focusing on the development of treatments for women with endometriosis.

"I am pleased to announce this new partnership between St. Joseph's Hospital and InNexus to explore, develop and commercialize new therapeutic solutions for women," said Jeff Morhet, Chairman and CEO of InNexus Biotechnology, "We've already identified our first project, aimed at providing new treatments to attack the problem of endometriosis, a painful condition that can lead to other conditions, such as infertility."

"We're excited to join InNexus in pursuing new treatments to help women with endometriosis," said Linda Hunt, President of St. Joseph's. "We hope this is the first of many collaborations that will ultimately help patients in need."

Scientific activities of the partnership will be conducted in facilities of both St. Joseph's Hospital and Medical Center and InNexus' GLP (Good Lab Practice) certified drug development laboratories with funding provided by research grants, the partners and strategic collaborators, the companies said.

Additional details were not disclosed.

((Comments on this story may be sent to newsdesk@closeupmedia.com))

((Distributed via M2 Communications Ltd - http://www.m2.com))

http://www.10meters.com

Comments on this story may be sent to newsdesk@closeupmedia.com

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index